Robert A. Jolly

机构：Eli Lilly (United States) · ORCID：0000-0001-7106-830X

发表论文 64 篇 · 总被引 2586 次 · h-index 27

代表论文

• In silico toxicology protocols (2018 · Regulatory Toxicology and Pharmacology · 被引 245)
• Principles and procedures for implementation of ICH M7 recommended (Q)SAR analyses (2016 · Regulatory Toxicology and Pharmacology · 被引 113)
• In silico methods combined with expert knowledge rule out mutagenic potential of pharmaceutical impurities: An industry survey (2012 · Regulatory Toxicology and Pharmacology · 被引 87)
• Identifying toxic mechanisms using DNA microarrays: evidence that an experimental inhibitor of cell adhesion molecule expression signals through the aryl hydrocarbon nuclear receptor (2002 · Toxicology · 被引 86)
• Genetic toxicology in silico protocol (2019 · Regulatory Toxicology and Pharmacology · 被引 84)
• Boronic Acids and Derivatives—Probing the Structure–Activity Relationships for Mutagenicity (2015 · Organic Process Research & Development · 被引 72)